Compare · MRAI vs PGNY
MRAI vs PGNY
Side-by-side comparison of Marpai Inc. (MRAI) and Progyny Inc. (PGNY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRAI and PGNY operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- PGNY is the larger of the two at $2.02B, about 46.5x MRAI ($43.5M).
- PGNY has been more active in the news (25 items in the past 4 weeks vs 9 for MRAI).
- PGNY has more recent analyst coverage (25 ratings vs 0 for MRAI).
- Company
- Marpai Inc.
- Progyny Inc.
- Price
- $0.92-55.67%
- $25.88+0.29%
- Market cap
- $43.5M
- $2.02B
- 1M return
- -
- +14.80%
- 1Y return
- -
- +15.41%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2019
- News (4w)
- 9
- 25
- Recent ratings
- 0
- 25
Marpai Inc.
Marpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market. It also offers ancillary services, such as care management, case management, actuarial services, health savings account administration, and cost containment services. The company was incorporated in 2021 and is based in Tampa, Florida.
Progyny Inc.
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Latest MRAI
- Director Eitan Yaron returned 50,000 shares to the company and was granted 175,000 shares, decreasing direct ownership by 4% to 1,224,073 units (SEC Form 4)
- Chief Financial Officer Johnson Steve Andrew was granted 125,000 shares and bought $682 worth of shares (1,100 units at $0.62), increasing direct ownership by 14% to 1,024,192 units (SEC Form 4)
- Director Shiv Sagiv returned 50,000 shares to the company and was granted 125,000 shares, decreasing direct ownership by 8% to 613,667 units (SEC Form 4)
- Director Pons Robert M returned 50,000 shares to the company and was granted 100,000 shares, decreasing direct ownership by 9% to 484,200 units (SEC Form 4)
- Director Calabrese Jennifer Rosario returned 50,000 shares to the company and was granted 100,000 shares, decreasing direct ownership by 18% to 225,000 units (SEC Form 4)
- Chief Executive Officer Lamendola Damien was granted 300,000 shares, increasing direct ownership by 22% to 1,650,000 units (SEC Form 4)
- Director Diclaudio Colleen was granted 125,000 shares, increasing direct ownership by 88% to 267,500 units (SEC Form 4)
- Marpai Inc. Announces Unprecedented Growth with 192,000 New Estimated Member Lives Across TPA and MarpaiRx PBM Platforms; Expects to Achieve Positive Cash Flow and EBITDA Beginning August 2026
- Director Eitan Yaron bought $2,700 worth of shares (10,000 units at $0.27), increasing direct ownership by 0.92% to 1,099,073 units (SEC Form 4)
- SEC Form 10-Q filed by Marpai Inc.
Latest PGNY
- Amendment: SEC Form SCHEDULE 13G/A filed by Progyny Inc.
- CHIEF FINANCIAL OFFICER Livingston Mark S. covered exercise/tax liability with 1,421 shares and sold $64,184 worth of shares (2,517 units at $25.50) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 74,688 units (SEC Form 4) (tax withholding)
- EVP, GC Swartz Allison covered exercise/tax liability with 1,015 shares and sold $45,022 worth of shares (1,798 units at $25.04) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 82,378 units (SEC Form 4) (for withholding tax)
- CHIEF EXECUTIVE OFFICER Anevski Peter covered exercise/tax liability with 5,361 shares, decreasing direct ownership by 0.66% to 811,472 units (SEC Form 4) to satisfy tax liability
- CHIEF FINANCIAL OFFICER Livingston Mark S. covered exercise/tax liability with 158 shares and sold $7,310 worth of shares (279 units at $26.20) as part of a pre-agreed trading plan, decreasing direct ownership by 0.55% to 78,626 units (SEC Form 4) (withholding tax)
- Director Scott Cheryl exercised 14,667 shares at a strike of $13.00, covered exercise/tax liability with 7,228 shares and sold $196,278 worth of shares (7,439 units at $26.39) (SEC Form 4)
- Chief Product Officer Clapp Geoffrey sold $39,137 worth of shares (1,530 units at $25.58), exercised 12,909 shares at a strike of $20.91 and covered exercise/tax liability with 11,379 shares (SEC Form 4) (for tax liability)
- EVP, GC Swartz Allison covered exercise/tax liability with 1,352 shares and sold $61,053 worth of shares (2,398 units at $25.46) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 85,191 units (SEC Form 4) to cover withholding tax
- Director Gordon Kevin K sold $137,445 worth of shares (5,500 units at $24.99), disposed of 2,526 shares and acquired 2,526 shares, decreasing direct ownership by 54% to 6,792 units (SEC Form 4)
- New Progyny Study Shows Growing Demand for Human Guidance in an Increasingly Digital Healthcare System